\nL\u2019une des pr\u00e9sentations cl\u00e9s (Abstract H14)<\/b>, intitul\u00e9e \u00ab Development of a new and improved delivery system for lanreotide autogel\/depot to further enhance care for patients with NETs and acromegaly<\/b><\/em> \u00bb<\/b>, rend compte des r\u00e9sultats de cinq \u00e9tudes distinctes, mais compl\u00e9mentaires, mises en place pour d\u00e9tailler et tester les am\u00e9liorations apport\u00e9es \u00e0 l\u2019actuelle seringue pr\u00e9-remplie Somatuline\u00ae Autogel\u00ae (lanr\u00e9otide).1
\nLes renseignements fournis par les patients et leurs aidants, ainsi que par les infirmiers et d\u2019autres professionnels de sant\u00e9, ont \u00e9t\u00e9 utilis\u00e9s pour la conception d\u2019une nouvelle seringue pr\u00e9-remplie1 qui a \u00e9t\u00e9 pr\u00e9sent\u00e9e \u00e0 l\u2019Union europ\u00e9enne dans le cadre d\u2019une variation de type II par le biais d\u2019une proc\u00e9dure de travail partag\u00e9 avec l\u2019HPRA (Irlande) comme pays de r\u00e9f\u00e9rence. Compte tenu des r\u00e9sultats positifs de cette proc\u00e9dure, chaque \u00c9tat membre envisagera une approbation nationale. Parmi les nouvelles fonctionnalit\u00e9s importantes, l\u2019on peut citer les modifications apport\u00e9es \u00e0 l\u2019ergonomie et \u00e0 la manipulation, un nouveau syst\u00e8me de retrait du protecteur d\u2019aiguille, un proc\u00e9d\u00e9 d\u2019injection avec support de piston et une am\u00e9lioration de la facilit\u00e9 d\u2019utilisation.1<\/p>\n
\u00ab Notre mission est de nous assurer que les patients atteints de TNE ou d\u2019acrom\u00e9galie continuent de recevoir les meilleurs soins pour venir \u00e0 bout des difficult\u00e9s qu\u2019ils rencontrent, \u00bb<\/em> d\u00e9clare Sotirios Stergiopoulos, Chief Medical Officer d\u2019Ipsen. \u00ab Les donn\u00e9es que nous allons pr\u00e9senter cette ann\u00e9e \u00e0 l\u2019occasion de la conf\u00e9rence de l\u2019ENETS t\u00e9moignent de notre engagement \u00e0 prendre en compte l\u2019exp\u00e9rience des patients et \u00e0 favoriser une approche th\u00e9rapeutique pluridisciplinaire pour faciliter autant que possible l\u2019administration du traitement, qu\u2019il se fasse \u00e0 l\u2019h\u00f4pital ou \u00e0 domicile. \u00bb<\/em><\/p><\/blockquote>\n
\u00ab Pour les infirmiers et autres professionnels de sant\u00e9 qui prennent en charge des patients atteints de TNE ou d\u2019acrom\u00e9galie, les innovations \u00e0 tous les niveaux du traitement permettent de fournir les meilleurs soins aux patients, \u00bb <\/em>d\u00e9clare Daphne T Adelman, Infirmi\u00e8re clinique sp\u00e9cialiste \u00e0 la Northwestern University de Chicago, \u00c9tats-Unis, qui fait partie des auteurs de l\u2019\u00e9tude. \u00ab En tant qu\u2019infirmi\u00e8re charg\u00e9e d\u2019administrer les traitements, l\u2019utilisation de seringues pr\u00e9-remplies me fait gagner un temps pr\u00e9cieux que je peux consacrer aux besoins de mes patients. \u00bb<\/em><\/p><\/blockquote>\n
Les r\u00e9sultats des \u00e9tudes suivantes seront \u00e9galement pr\u00e9sent\u00e9s :
\n(Abstract #H18) Tumour growth rate (TGR) to monitor growth\/predict response to lanreotide autogel (LAN) use before, during and after peptide receptor radionuclide therapy (PRRT) in advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs): data from PRELUDE<\/b><\/p>\nCet abstract a \u00e9t\u00e9 s\u00e9lectionn\u00e9 pour une pr\u00e9sentation de poster dans le cadre du programme scientifique de l\u2019ENETS et d\u00e9taillera les donn\u00e9es d\u2019efficacit\u00e9 et les analyses post-hoc du taux de croissance des tumeurs (TGR), en tant que mesure d\u2019\u00e9valuation de la r\u00e9ponse \u00e0 la LAN-PRRT (lanr\u00e9otide autogel \u2013 th\u00e9rapie radionucl\u00e9ide par r\u00e9cepteur de peptide).<\/p>\n
(Abstract #M03) ATLANT, phase 2 study combination trial between long acting somatostatin analogue (SSA) lanreotide (LAN) and temozolomide (TMZ) in progressive thoracic (lung \/ thymus) well differentiated NET (carcinoid) (TNETS)<\/b>.<\/p>\n
(Abstract #F22) Exploratory assessment of the clinical value of baseline (BL) circulating tumour cells (CTC) to predict symptomatic response in pts with functioning midgut neuroendocrine tumours (NETs) receiving lanreotide autogel (LAN): CALM-NET study results<\/b><\/p>\n
En plus de ces posters, Ipsen pr\u00e9sentera \u00e9galement les donn\u00e9es de 13 \u00e9tudes parrain\u00e9es ou soutenues par l\u2019entreprise, et analyses de la litt\u00e9rature suivantes :<\/p>\n
(Abstract #H17) Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel\/Depot (LAN) For Patients With Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: The Prospective, Open-label, International, Phase 2 CLARINET FORTE Study<\/b><\/p>\n
(Abstract #P04) Lanreotide autogel 120mg (LAN) in patients (pts) with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NETs): prospective observational NETways study<\/b><\/p>\n
(Abstract #D13) Satisfaction Survey of Administration Modes for Long-Acting (LA) Somatostatin Analog (SSA) Therapy in Patients (pts) with Neuroendocrine Tumuors (NETs): Results of Cognitive Interviews With Patients and Nurses<\/b><\/p>\n
(Abstract #J15) The Effect of Carcinoid Syndrome Diarrhea (CSD) Interventions on Patient Experience Outcomes: a Systematic Literature Review (SLR)<\/b><\/p>\n
(Abstract #J08) Differential Diagnosis (DDx) of Carcinoid Syndrome Diarrhea (CSD): a Systematic Literature Review (SLR)<\/b><\/p>\n
(Abstract #H25) Evaluation of the use of resources and costs associated with Uncontrolled or Controlled Carcinoid Syndrome (CS) in patients (pts) with Neuroendocrine Tumours (NETs) in Spain: RECOSY study<\/b><\/p>\n
(Abstract #F10) Relationship between biomarkers and number of liver metastases at the time of diagnosis of small intestinal neuroendocrine tumors<\/b><\/p>\n
(Abstract #A11) Evaluation of gene expression changes associated with response to somatostatin analogues (SSAs) in gastrointestinal (GI) neuroendocrine tumors (NETs)<\/b><\/p>\n
(Abstract #J07) Long-term Treatment with Telotristat Ethyl (TE) in Patients with Carcinoid Syndrome (CS) Symptoms: Results from TELEPATH Study<\/b><\/p>\n
(Abstract #P05) TELEFIRST: A randomized phase III clinical trial of Lanreotide (LAN) combined with Telotristat ethyl (TE) or placebo (PBO) for the First-line treatment in patients (pts) with advanced well-differentiated (wd) small intestinal neuroendocrine tumours (siNET) with highly-functioning carcinoid syndrome (CS)<\/b><\/p>\n
(Abstract #K30) OPS-C-001: A Phase I\/II Study To Investigate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor (SSTR)-Positive Neuroendocrine Tumours (NETs)<\/b><\/p>\n
(Abstract #P08) Study to evaluate the optimal dose of 68Ga-OPS202 as a PET imaging agent in patients with GEP-NETs<\/b><\/p>\n
(Abstract #D33) Establishment of a NET data base in a German tertiary referral center; preliminary results<\/b><\/p>\n
Pi\u00e8ce jointe<\/strong><\/p>\n
<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[1233,3556],"tags":[],"class_list":["post-37038","press_release","type-press_release","status-publish","hentry","category-pressrelease-fr","category-corporate-pressrelease-fr","entry"],"acf":[],"yoast_head":"\n